Tubize-Fin (TUB) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.001x

Based on the latest financial reports, Tubize-Fin (TUB) has a cash flow conversion efficiency ratio of -0.001x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.41 Million ≈ $-2.81 Million USD) by net assets (€1.89 Billion ≈ $2.20 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Tubize-Fin net asset quality index to measure how much of total assets are equity-financed.

Tubize-Fin - Cash Flow Conversion Efficiency Trend (2004–2025)

This chart illustrates how Tubize-Fin's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Tubize-Fin (TUB) cash flow quality to evaluate the quality of earnings relative to operating cash generation.

Tubize-Fin Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Tubize-Fin ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
JAPAN EX UN.ADR 1/2 O.N.
F:OSKU
N/A
Sanlam Ltd
JSE:SLM
0.114x
Confluent Inc
NASDAQ:CFLT
0.036x
SUBARU CORP. ADR/1/2
F:FUH0
N/A
Anker Innovations Technology Co Ltd
SHE:300866
0.044x
China Shipbuilding Industry Group Power Co Ltd
SHG:600482
0.044x
Old Republic International Corp
NYSE:ORI
0.047x
Equatorial Energia S.A
SA:EQTL3
0.024x

Annual Cash Flow Conversion Efficiency for Tubize-Fin (2004–2025)

The table below shows the annual cash flow conversion efficiency of Tubize-Fin from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see TUB company net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 €1.89 Billion
≈ $2.20 Billion
€91.84 Million
≈ $107.37 Million
0.049x +4432.70%
2024-12-31 €1.84 Billion
≈ $2.15 Billion
€-2.07 Million
≈ $-2.42 Million
-0.001x +1.28%
2023-12-31 €1.80 Billion
≈ $2.10 Billion
€-2.05 Million
≈ $-2.39 Million
-0.001x -101.14%
2022-12-31 €1.75 Billion
≈ $2.05 Billion
€174.23 Million
≈ $203.69 Million
0.099x +27868.38%
2021-12-31 €3.25 Billion
≈ $3.80 Billion
€-1.16 Million
≈ $-1.36 Million
0.000x +52.23%
2020-12-31 €2.79 Billion
≈ $3.27 Billion
€-2.09 Million
≈ $-2.45 Million
-0.001x -74.16%
2019-12-31 €2.66 Billion
≈ $3.11 Billion
€-1.15 Million
≈ $-1.34 Million
0.000x -101.33%
2018-12-31 €2.34 Billion
≈ $2.74 Billion
€75.76 Million
≈ $88.57 Million
0.032x -6.11%
2017-12-31 €2.12 Billion
≈ $2.47 Billion
€72.96 Million
≈ $85.30 Million
0.034x -0.28%
2016-12-31 €1.96 Billion
≈ $2.29 Billion
€67.70 Million
≈ $79.15 Million
0.035x +6.14%
2015-12-31 €1.95 Billion
≈ $2.28 Billion
€63.45 Million
≈ $74.18 Million
0.033x +8720.77%
2014-12-31 €1.62 Billion
≈ $1.90 Billion
€-613.00K
≈ $-716.66K
0.000x +28.75%
2013-12-31 €1.55 Billion
≈ $1.81 Billion
€-823.00K
≈ $-962.17K
-0.001x +43.61%
2012-12-31 €1.49 Billion
≈ $1.74 Billion
€-1.40 Million
≈ $-1.64 Million
-0.001x -1274.66%
2011-12-31 €1.55 Billion
≈ $1.81 Billion
€124.00K
≈ $144.97K
0.000x +110.32%
2010-12-31 €1.44 Billion
≈ $1.69 Billion
€-1.12 Million
≈ $-1.31 Million
-0.001x +91.77%
2009-12-31 €1.36 Billion
≈ $1.59 Billion
€-12.79 Million
≈ $-14.96 Million
-0.009x -311.75%
2008-12-31 €1.20 Billion
≈ $1.40 Billion
€5.32 Million
≈ $6.22 Million
0.004x +0.18%
2007-12-31 €1.26 Billion
≈ $1.47 Billion
€5.61 Million
≈ $6.55 Million
0.004x -98.16%
2006-12-31 €1.36 Billion
≈ $1.58 Billion
€327.96 Million
≈ $383.42 Million
0.242x +1799.40%
2005-12-31 €901.39 Million
≈ $1.05 Billion
€-12.84 Million
≈ $-15.01 Million
-0.014x -376.61%
2004-12-31 €592.56 Million
≈ $692.76 Million
€3.05 Million
≈ $3.57 Million
0.005x --

About Tubize-Fin

BR:TUB Belgium Biotechnology
Market Cap
$10.88 Billion
€9.30 Billion EUR
Market Cap Rank
#2297 Global
#9 in Belgium
Share Price
€209.00
Change (1 day)
+2.65%
52-Week Range
€141.20 - €247.50
All Time High
€247.50
About

Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous system. The company was founded in 1928 and is based in Brussels, Belgium.